Cogmotos, Inc. | 46 followers on LinkedIn. AI-driven CNS/aging platform. Programs: Postop delirium (clinical); Alzheimer’s (near clinic). New mechanisms of action. | Cogmotos has a clinical-stage, AI-enabled CNS / aging platform based on components with proof of concept in placebo-controlled clinical trials. The first stage of our platform involves intranasal, direct-to-brain delivery of peptides that has been proven out and cited widely in the literature. We have an ambitious agenda, targeting clinical data / exit options with a new class of Alzheimer drug in 4 years.